CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
Spark Therapeutics’ lead clinical asset is SPK-8011, a novel gene therapy for the treatment of hemophilia A, which is expected to start phase three trials this year.
Roche, +41 61 681 9320
Spark Therapeutics, 215-220-9300
Pages: 1 2
Spark Therapeutics’ lead clinical asset is SPK-8011, a novel gene therapy for the treatment of hemophilia A, which is expected to start phase three trials this year.
Roche, +41 61 681 9320
Spark Therapeutics, 215-220-9300
Tagged with: Roche Spark Therapeutics